317 related articles for article (PubMed ID: 10048399)
1. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
[No Abstract] [Full Text] [Related]
2. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
3. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
4. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells.
Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D
Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454
[No Abstract] [Full Text] [Related]
6. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
Ramsey WJ; Mullen CA; Blaese RM
Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
9. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
Taupin P
IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
[TBL] [Abstract][Full Text] [Related]
10. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
11. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
Kohn DB; Weinberg KI; Nolta JA; Heiss LN; Lenarsky C; Crooks GM; Hanley ME; Annett G; Brooks JS; el-Khoureiy A
Nat Med; 1995 Oct; 1(10):1017-23. PubMed ID: 7489356
[TBL] [Abstract][Full Text] [Related]
12. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for adenosine deaminase deficiency.
Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of gene therapy for SCID is being confirmed.
Cavazzana-Calvo M; Fischer A
Lancet; 2004 Dec 18-31; 364(9452):2155-6. PubMed ID: 15610783
[No Abstract] [Full Text] [Related]
16. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
Gaspar HB
Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
19. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
20. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]